Ticagrelor/Strong CYP3A4 Inhibitors
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your body processes ticagrelor.
What might happen:
The amount of ticagrelor in your blood may increase, which may increase your risk of bleeding.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together. Let your doctor know if you have any signs of stroke (sudden numbness/weakness of arm/leg/face, confusion, difficulty speaking or understanding others, sudden difficulty in walking or loss of balance/co-ordination, sudden dizziness or severe headache), unusual bleeding or bruising (nosebleeds, bleeding from the gums or eyes, black or tarry stools), or you feel short of breath.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Brilique (ticagrelor) UK summary of product characteristics. AstraZeneca UK Limited October 24, 2012.
2.Brilinta (ticagrelor) US prescribing information. AstraZeneca LP March, 2013.
3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.